Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radvax autologous tumor vaccine in advanced solid cancers
NCT05807035Phase 1Recruiting
- Sponsor
- Vaxine
- Start
- Feb 2023
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Radvax in solid tumor and lymphoma, sponsored by Vaxine. Primary endpoint: Incidence of grade 3 or 4 adverse effects at 7 days. Started Feb 2023; status: recruiting.
02
Drugs
Radvax
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05807035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807035.